Publicaciones Similares
Biosimilars in Mexico
The regulatory body for the approval of
medicines in Mexico is the Federal Commission for Protection Against Health Risks (COFEPRIS)
Brazilian Health System
Guarantees universal access to health and finances the system through taxes through the Unified Health System (SUS) and a private sector.
Chilean Health System
Contribute to preserving and improving the health of the population, especially through its personal and collective care services, which seek to be a coherent response to the health and health care needs of the various population groups.
Biosimilars in Brazil
Brazil has designed a set of measures to increase investment in biopharmaceutical research and is promoting the production of national biological drugs.
Rare Diseases – Orphan drugs- innovative- models of procurement for rare diseases- pricing and reimbursement in Latin America
Orphan drugs used to treat rare diseases have been labeled “orphan drugs” because of their applicability to very small populations, and they respond to public health needs
Rare Diseases current situation in Latin America and the global drug market
The size of the global market in 2021 for the treatment of rare diseases was valued at USD 119.600 million it is expected to increase at a compound annual growth rate (CAGR) of 12.8% between 2022 and 2030.